Jazz Pharmaceuticals price target lowered to $200 from $230 at Barclays

Barclays lowered the firm’s price target on Jazz Pharmaceuticals to $200 from $230 and keeps an Overweight rating on the shares post the Q1 report. While the guidance was reaffirmed, the stock is unlikely to rerate on on the quarter and needs multiple pipeline catalysts to play out, including Zani, the analyst tells investors in a research note.